## **PURPOSE:**

The information contained in this publication was obtained from various sources within the Food and Drug Administration (FDA) throughout the course of the fiscal year and updated up to the time of publication. While reasonable steps were taken to assure the information was correct at the time of publication, the statements in the publication may not contain all significant information on any cited account.

Further, this publication does not contain all enforcement actions under taken by the FDA during the fiscal year. All items are presented in a summary form to convey the significance of the violation and/or court decision(s). The Enforcement Story is devoted to practical presentation of the actual FDA enforcement actions that impact on the development, manufacture, distribution and marketing of foods, drugs, biologics, cosmetics, and medical devices.

The Enforcement Story is intended as a publication to serve as an information source. The statements made herein are not intended to create or confer any rights, privileges, or benefits on or for any private person.

## DISTRIBUTION WITHIN THE FDA:

FDA Personnel may obtain copies of The Enforcement Story by contacting the Division of Compliance Information and Quality Assurance (HFC-240) in the ORA's Office of Enforcement.

## **PUBLIC DISTRIBUTION:**

The public may only obtain a copy of The Enforcement Story by making a written Freedom of Information request.

## **COMMENTS:**

Any comments as to how this annual publication may be improved are welcomed. Please send your comments to the Director, Division of Compliance Information and Quality Assurance, Suite 140/(HFC-240), 15800 Crabbs Branch Way, Rockville, MD 20855-2604.